Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS)
| Previous close | 17.92 |
| Open | 17.96 |
| Bid | 18.87 x N/A |
| Ask | 18.88 x N/A |
| Day's range | 17.61 - 18.89 |
| 52-week range | 12.47 - 26.00 |
| Volume | |
| Avg. volume | 4,707,598 |
| Market cap | 7.699B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 75.52 |
| EPS (TTM) | 0.25 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.06 |
PR NewswireNational Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), has been officially approved by the National Medical Products Administration (NMPA) for treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) with positive
PR NewswirePositive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024. The primary efficacy endpoint of the trial has been achieved, and further data analysis is currently underway.
PR NewswireChipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors
Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution. The trial is a multi-center, non-randomized, open-label, multi-dose phase I clinical trial designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic properties, and potential biomarkers as
